Novo Nordisk Appoints Alan C. Moses as Chief Medical Officer Worldwide
Novo Nordisk announced the appointment of Alan C. Moses, M.D. as vice president, chief medical officer worldwide. Moses is currently the chief medical officer of Novo Nordisk Inc., the company's U.S. affiliate.
In the newly expanded role, Moses will work closely with senior colleagues in Denmark to serve as the principle voice of clinical science for the company worldwide, providing clinical and medical affairs expertise.
Moses was formerly senior vice president and chief medical officer at the Joslin Diabetes Center and joined Novo Nordisk in April 2004 as associate vice president of medical affairs and since then has also assumed responsibility for clinical research in diabetes. Prior to joining Novo Nordisk, Dr. Moses spent 23 years at Harvard Medical School-affiliated institutions where he rose to the rank of Professor of Medicine. He has written more than 100 peer-reviewed articles on the treatment of diabetes and has been recognized both locally and nationally for his research in diabetes and growth factors.
Moses received a Bachelor of Science from Duke University and a Medical Doctorate from Washington University School of Medicine prior to training at Barnes Hospital in St. Louis, the National Institutes of Health in Bethesda, Md., and Tufts-New England Medical Center in Boston. He is board certified by the American Board of Internal Medicine and has a subspecialty certification in Endocrinology and Metabolism.
Other news from the department people
